TOP
0
0
即日起~6/30,暑期閱讀書展,好書7折起
Detection And Quantification Of Antibodies To Biopharmaceuticals: Practical And Applied Considerations
滿額折

Detection And Quantification Of Antibodies To Biopharmaceuticals: Practical And Applied Considerations

商品資訊

定價
:NT$ 7873 元
優惠價
907086
若需訂購本書,請電洽客服 02-25006600[分機130、131]。
相關商品
商品簡介
作者簡介
目次

商品簡介

Drugs containing genetically modified biological matter carry the risk that the patient's immune system will treat it as a foreign body and create antibodies to counteract it. Here researchers in pharmaceuticals and related fields provide information on detecting and quantifying such antibodies in clinical trials. They cover risk-based strategies, regulatory requirements, principal technologies employed for quantifying anti-drug antibodies, assay standardization and validation, statistical considerations, adapting anti-drug antibody assays to challenging conditions, and novel technologies for quantifying neutralizing antibodies. Annotation c2011 Book News, Inc., Portland, OR (booknews.com)

作者簡介

MICHAEL G. TOVEY, PhD, INSERM Director of Research in the Laboratory of Biotechnology and Applied Pharmacology, Ecole Normale Superieure de Cachan, France. He is an Associate Editor of the Journal of Interferon and Cytokine Research and author of more than two hundred articles on interferon, cytokines, and biotechnology.

目次

Introduction. Neutralizing Antibody Assays: A Perspective (Michael G. Tovey).

Section I – Risk-Based Strategies.

Chapter 1. Principles of Risk Assessment and Monitoring of Antibody Responses to Biopharmaceuticals (Eugen Koren, Erik Foehr, and Charles A. O’Neill).

Section II – Regulatory Requirements.

Chapter 2. Immunogenicity of Therapeutic Proteins: A Regulatory Perspective (Susan Kirshner).

Chapter 3. Guidance on Immunogenicity Assessment of Biologically-Derived Therapeutic Proteins: An European Perspective (Meenu Wadhwa and Robin Thorpe).

Chapter 4. Japanese Regulatory Perspective on Immunogenicity (Takao Hayakawa and Akiko Ishii).

Section III – Principal Technologies Employed for the Quantification of Anti-Drug Antibodies.

Chapter 5. Enzyme Immunoassays and Radioimmune Assays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies (Klaus Bendtzen and Morten Svenson).

Chapter 6. Confirmatory Immunogenicity Assays (Eric Wakshull and Daniel Coleman).

Chapter 7. The Use of Pharmacodynamics as a Surrogate Marker for the Detection of Anti-Drug Neutralizing Antibodies (Florian Deisenhammer).

Chapter 8. Cell-based assays for the Detection of Neutralizing Antibodies to Interferon beta (IFN-ß) and Tumor Necrosis Factor-alpha (TNF-a) Inhibitors (Anthony Meager).

Chapter 9. Detection of Neutralizing Antibodies (NABs) to Interferon-Beta by Real Time RT-PCR (Francesca Gilli, and Antonio Bertolotto).

Chapter 10. Competitive Ligand Binding Assays for the Detection of Neutralizing Antibodies (Bonnie Wu, George R. Gunn, and Gopi Shankar).

Chapter 11. The Use of Surface Plasmon Resonance for the Detection and Characterization of Antibodies (Steven J. Swanson and Daniel Mytych).

Chapter 12. Hypersensitivity Reactions to Biopharmaceuticals: Detection and Quantification of drug-Specific IgE Antibodies (Jörgen Dahlström and Lennart Venemalm).

Section IV. Assay Standardization and Validation.

Chapter 13. Standardization and Validation of Immunoassays and Biophysical Assays for the Detection of Anti-drug Antibodies (Daniel Kramer).

Chapter 14. Standardization and Validation of Cell-Based Assays for the Detection of Neutralizing Anti-drug Antibodies (Deborah Finco-Kent and Amy Grenham).

Chapter 15. Standardization of Neutrializing Antodody Unitge by Bioassay Design: Constant Antigen and Constant Antibody Methodology (Sidney E. Grossberg, Yoshimi Kawade and Leslie D. Grossberg).

Section V. Statistical Considerations.

Chapter 16. Cut-Points and Performance Characteristics for Anti-Drug Antibody Assays (Viswanath Devanarayan and Michael G. Tovey).

Chapter 17. Dilutional Linearity for Neutralizing Antibody Assays (David Lansky and Carrie Wager).

Section VI. Adaptation of Neutralization Assays to Challenging Conditions.

Chapter 18. Detection of Neutralizing Antibodies to Biopharmaceuticals in the Presence of High Levels of Circulating Drug (Arno Kromminga and Michael G. Tovey).

Chapter 19. Antibody Assays in Animal Researc (Vera Brinks, Francesca Gilli, Melody Sauerborn, and Huub Schellekens).

Chapter 20. Immunogenicity of Microbial Digestive Enzymes for Oral Replacement Therapy in Pancreatic Exocrine Insufficiency (Claudia Berger and Uwe Niesner).

Section VII. Novel Technologies for the Quantification of Neutralizing Antibodies.

Chapter 21. Drug Quantification Based-Assay for Neutralizing Antibodies (Yao Zhuang and Shalini Gupta).

Chapter 22. A Novel O ne-Step Cell-Based Assay for the Quantification of Neutralizing Antibodies to Biopharmaceuticals (Christophe Lallemand and Michael G. Tovey).

您曾經瀏覽過的商品

購物須知

外文書商品之書封,為出版社提供之樣本。實際出貨商品,以出版社所提供之現有版本為主。部份書籍,因出版社供應狀況特殊,匯率將依實際狀況做調整。

無庫存之商品,在您完成訂單程序之後,將以空運的方式為你下單調貨。為了縮短等待的時間,建議您將外文書與其他商品分開下單,以獲得最快的取貨速度,平均調貨時間為1~2個月。

為了保護您的權益,「三民網路書店」提供會員七日商品鑑賞期(收到商品為起始日)。

若要辦理退貨,請在商品鑑賞期內寄回,且商品必須是全新狀態與完整包裝(商品、附件、發票、隨貨贈品等)否則恕不接受退貨。

優惠價:90 7086
若需訂購本書,請電洽客服 02-25006600[分機130、131]。

暢銷榜

客服中心

收藏

會員專區